Eli Lilly Finalizes $2.75 Billion AI Drug Discovery Deal with Insilico Medicine
Global pharmaceutical company Eli Lilly has finalized a $2.75 billion agreement to expand its partnership with Insilico Medicine, licensing an early-stage drug pipeline and utilizing Insilico's artificial intelligence platform for drug development to bring AI-developed medicines to market, with new reports confirming the deal.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (80/100)Sources
Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery - Reuters
Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery Reuters
Read full article →Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com
Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion Bloomberg.com
Read full article →Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in China
Read full article →Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.
Read full article →Hong Kong-listed Insilico Medicine signs AI drug development deal with Eli Lilly
Insilico Medicine has signed a potential multibillion-dollar deal with Eli Lilly to license out an early-stage drug pipeline and provide its artificial intelligence platform services in research and development collaborations. Under the agreement announced on Monday, US-headquartered, Hong Kong-listed Insilico will receive an upfront payment of US$115 million. The deal could have a total value of around US$2.75 billion tied to development, regulatory and commercial milestones, plus tiered...
By Julie Zhang
Read full article →
